1
|
Rahban M, Habibi-Rezaei M, Mazaheri M, Saso L, Moosavi-Movahedi AA. Anti-Viral Potential and Modulation of Nrf2 by Curcumin: Pharmacological Implications. Antioxidants (Basel) 2020; 9:E1228. [PMID: 33291560 PMCID: PMC7761780 DOI: 10.3390/antiox9121228] [Citation(s) in RCA: 40] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2020] [Revised: 11/29/2020] [Accepted: 12/01/2020] [Indexed: 12/13/2022] Open
Abstract
Nuclear factor erythroid 2-related factor 2 (Nrf2) is an essential transcription factor that maintains the cell's redox balance state and reduces inflammation in different adverse stresses. Under the oxidative stress, Nrf2 is separated from Kelch-like ECH-associated protein 1 (Keap1), which is a key sensor of oxidative stress, translocated to the nucleus, interacts with the antioxidant response element (ARE) in the target gene, and then activates the transcriptional pathway to ameliorate the cellular redox condition. Curcumin is a yellow polyphenolic curcuminoid from Curcuma longa (turmeric) that has revealed a broad spectrum of bioactivities, including antioxidant, anti-inflammatory, anti-tumor, and anti-viral activities. Curcumin significantly increases the nuclear expression levels and promotes the biological effects of Nrf2 via the interaction with Cys151 in Keap1, which makes it a marvelous therapeutic candidate against a broad range of oxidative stress-related diseases, including type 2 diabetes (T2D), neurodegenerative diseases (NDs), cardiovascular diseases (CVDs), cancers, viral infections, and more recently SARS-CoV-2. Currently, the multifactorial property of the diseases and lack of adequate medical treatment, especially in viral diseases, result in developing new strategies to finding potential drugs. Curcumin potentially opens up new views as possible Nrf2 activator. However, its low bioavailability that is due to low solubility and low stability in the physiological conditions is a significant challenge in the field of its efficient and effective utilization in medicinal purposes. In this review, we summarized recent studies on the potential effect of curcumin to activate Nrf2 as the design of potential drugs for a viral infection like SARS-Cov2 and acute and chronic inflammation diseases in order to improve the cells' protection.
Collapse
Affiliation(s)
- Mahdie Rahban
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran;
| | - Mehran Habibi-Rezaei
- School of Biology, College of Science, University of Tehran, Tehran 1417614335, Iran
- Center of Excellence in NanoBiomedicine, University of Tehran, Tehran 1417614335, Iran
| | - Mansoureh Mazaheri
- Research Center of Food Technology and Agricultural Products, Department of Food Toxicology, Standard Research Institute, Karaj 3158777871, Iran;
| | - Luciano Saso
- Department of Physiology and Pharmacology “Vittorio Erspamer”, Sapienza University of Rome, P. le Aldo Moro 5, 00185 Rome, Italy;
| | - Ali A. Moosavi-Movahedi
- Institute of Biochemistry and Biophysics, University of Tehran, Tehran 1417614335, Iran;
- UNESCO Chair on Interdisciplinary Research in Diabetes, University of Tehran, Tehran 1417614335, Iran
| |
Collapse
|
2
|
Fang W, Nasir Y. The effect of curcumin supplementation on recovery following exercise-induced muscle damage and delayed-onset muscle soreness: A systematic review and meta-analysis of randomized controlled trials. Phytother Res 2020; 35:1768-1781. [PMID: 33174301 DOI: 10.1002/ptr.6912] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2020] [Revised: 09/21/2020] [Accepted: 10/04/2020] [Indexed: 12/12/2022]
Abstract
BACKGROUND curcumin consumption may have a protective effect against exercise-induced muscle damage (EIMD) through stabilization of the cell membrane via inhibition of free radical formation. Evidence supporting a protective role of curcumin after physical activity induced muscle injury in humans, however, it is inconsistent. METHODS Medline, Scopus, and Google scholar were systematically searched up to May 2020. The Cochrane Collaboration tool for assessing the risk of bias was used for assessing the quality of studies. Random effects model, weighted mean difference (WMD), and 95% confidence interval (CI) were used for estimating the overall effect. Between-study heterogeneity was assessed using the chi-squared and I2 statistic. RESULTS The results revealed a significant effect of curcumin supplementation on reducing creatine kinase (CK) (weighted mean difference [WMD] = -48.54 IU.L-1 ; 95% CI: -80.667, -16.420; p = .003) and muscle soreness index decrease (WMD = -0.476; 95% CI: -0.750, -0.202; p = .001). Moreover, a subgroup analysis resulted in a significant decrease in CK concentrations and muscle soreness index, according to follow-ups after exercise, dose of curcumin, duration of studies, exercise type, train status and study design. CONCLUSIONS The current evidence revealed a efficacy of curcumin in reducing CK serum levels and muscle soreness index among adults. Therefore, curcumin may be known as a priority EIMD recovery agent in interventions.
Collapse
Affiliation(s)
- Wang Fang
- Henan University of Technology Sports Institute, Zhengzhou, Henan, China
| | - Yasaman Nasir
- Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
3
|
Chang R, Chen X, Yu H, Tan G, Wen H, Huang J, Hao Z. Modified EDTA selectively recognized Cu2+ and its application in the disaggregation of β-amyloid-Cu (II)/Zn (II) aggregates. J Inorg Biochem 2020; 203:110929. [DOI: 10.1016/j.jinorgbio.2019.110929] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 11/14/2019] [Accepted: 11/15/2019] [Indexed: 12/26/2022]
|
4
|
Shi L, Qu Y, Li Z, Fan B, Xu H, Tang J. In vitro Permeability and Bioavailability Enhancement of Curcumin by Nanoemulsion via Pulmonary Administration. Curr Drug Deliv 2019; 16:751-758. [DOI: 10.2174/1567201816666190717125622] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2019] [Revised: 05/28/2019] [Accepted: 06/23/2019] [Indexed: 12/21/2022]
Abstract
Background:
Curcumin has shown considerable pharmacological activity, including antiinflammatory
activity. Nevertheless, the pharmacological effect of curcumin may be limited because of
poor water solubility, metabolizing rapidly and systemic elimination.
Objective:
In the current research, a novel curcumin nanoemulsion (Cur-NE) was developed for improving
in vitro permeability and bioavailability via pulmonary administration.
Methods:
The Cur-NE was prepared by a modified emulsification-evaporation method and its surfac
morphology, particles size and distribution, and encapsulation efficiencies of drug in NE were characterized.
In vitro transmembrane transport experiment was performed to investigate the transport profile
of curcumin across Xenopus alveolar membrane. The pharmacokinetics of Cur-NE in rabbits was evaluated.
Results:
The average particles size, zeta potential, polydispersity index of Cur-NE were 234.8±1.08 nm,
-19.5±0.2 mV and 0.10, respectively. Xenopus alveolar membrane was used in the transmembrane
transport study, the cumulative amount of curcumin was 6.6% for curcumin suspensions, but nearly
50% for Cur-NE at the time of 8 h (P<0.05). The pharmacokinetic study in rabbits, the absolute
bioavailability of curcumin for Cur-NE was 24.11%.
Conclusion:
Thus, a novel Cur-NE for pulmonary drug delivery was developed for improving in vitro
permeability and bioavailability, which can be an alternate to the oral administration.
Collapse
Affiliation(s)
- Liying Shi
- Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, 150086, China
| | - Youyang Qu
- Department of Neurology, the Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China
| | - Zerong Li
- Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, 150086, China
| | - Bin Fan
- Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, 150086, China
| | - Hongfei Xu
- Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, 150086, China
| | - Jingling Tang
- Department of Pharmaceutics, School of Pharmacy, Harbin Medical University, Harbin, 150086, China
| |
Collapse
|
5
|
Kunnumakkara AB, Harsha C, Banik K, Vikkurthi R, Sailo BL, Bordoloi D, Gupta SC, Aggarwal BB. Is curcumin bioavailability a problem in humans: lessons from clinical trials. Expert Opin Drug Metab Toxicol 2019; 15:705-733. [DOI: 10.1080/17425255.2019.1650914] [Citation(s) in RCA: 84] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Ajaikumar B. Kunnumakkara
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Choudhary Harsha
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Kishore Banik
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Rajesh Vikkurthi
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Bethsebie L. Sailo
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Devivasha Bordoloi
- Cancer Biology Laboratory and DBT-AIST International Laboratory for Advanced Biomedicine (DAILAB), Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India
| | - Subash C. Gupta
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi, India
| | | |
Collapse
|
6
|
Kimura S, Kiriyama A, Nishimura E, Sakata S, Inoue D, Furubayashi T, Yutani R, Tanaka A, Kusamori K, Katsumi H, Iga K, Yamamoto A, Sakane T. Novel Strategy for the Systemic Delivery of Furosemide Based on a New Drug Transport Mechanism. Biol Pharm Bull 2018; 41:1769-1777. [DOI: 10.1248/bpb.b18-00315] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Shunsuke Kimura
- Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts
| | - Akiko Kiriyama
- Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts
| | - Erika Nishimura
- Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts
| | - Shiori Sakata
- Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts
| | | | | | - Reiko Yutani
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University
| | - Akiko Tanaka
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University
| | - Kosuke Kusamori
- Department of Biopharmaceutics, Kyoto Pharmaceutical University
| | | | - Katsumi Iga
- Department of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts
| | - Akira Yamamoto
- Department of Biopharmaceutics, Kyoto Pharmaceutical University
| | - Toshiyasu Sakane
- Department of Pharmaceutical Technology, Kobe Pharmaceutical University
| |
Collapse
|